If regular explanations of retirement concepts just aren't working, try a few pictures. If you put all the best minds in personal finance together and asked them to come up with a manual on money ...

Add Yahoo as a preferred source to see more of our stories on Google. For many high school seniors and their families, this spring is all about comparing college offers and figuring out what’s truly ...

KANSAS CITY, Mo – For many high school seniors and their families, this spring is all about comparing college offers and figuring out what’s truly affordable. Experts from Johnson County Community ...

HUNTINGDON Insurance series set The Huntingdon County Library is partnering with local insurance professionals to host a free “Insurance 101” educational series designed to help community members ...

I have been an advisor to physicians for 30 years, helping them shield assets from potential liability — first as an attorney ...

One Druids Heath resident said they would use their 'electoral power to hold decision-makers accountable' ...

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition ...

Hong Kong could emerge as the world’s leading financial centre as the central government pushes to internationalise the yuan – a move that will advance the nation’s development under the 15th ...

United Lithium Corp. (“United Lithium” or the “Company”) (CSE: ULTH; OTCQX: ULTHF; FWB: 0UL) is pleased to announce the filing of an independent National Instrument 43-101 – Standards of Disclosure ...

Net Underwriting Profit -- $13 million reported, yielding a combined ratio of 92.1% for the quarter. Net Income (Q4) -- $49.3 million, translating to $1.44 per diluted share. Innovations Segment -- ...

This shareholder letter follows the completion of our fourth quarter and fiscal year ended December 31, 2025.

Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen ...